Idera Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 89   

Articles published

IDRA 3.13
price chart
Idera Pharmaceuticals, Inc. Shares Soar On Earnings
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
Idera Pharmaceuticals Inc.: Idera Pharmaceuticals Reports First Quarter 2015 ...  The Wall Street Transcript
Idera Pharmaceuticals: Is The Writing On The Wall?
Idera Pharmaceuticals has shown recent successes in advancing their technology for treatment of many life threatening diseases, which makes it an attractive investment.
Biotech Stocks in News - Celladon (CLDN), Idera Pharmaceuticals (IDRA ...  Wall Street Observer
Idera Pharmaceuticals: A Star In The Making (IDRA)
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) is a biotechnology company engaged in discovering and developing Toll-Like Receptors (TLRs) antagonists, novel-synthetic DNA and RNA based drug candidates.
Related articles »  
Idera Pharmaceuticals Going Into 2015 (IDRA)
Idera Pharmaceuticals Inc. (NASDAQ:IDRA) is set to enter 2015 with a number of important developments happening during the year.
Related articles »  
1-Week Top Healthcare Stocks: KaloBios Pharmaceuticals Inc (NASDAQ:KBIO ...
Idera Pharmaceuticals Inc (NASDAQ:IDRA), saw its price movement on above normal volume, as 1.83 million shares changed hands when compared with its average daily volume of 1.64 million shares.
Stock Report on Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)
[Globe Newswire] Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)(TREND ANALYSIS) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for oncology and rare diseases, today ...
Healthcare Stocks Capture Market Intentions- Idera Pharmaceuticals, Inc ...
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) released that the achievement of input development milestones for its product candidate IMO-9200, an antagonist of Toll-like receptors (TLRs) 7, 8 and 9. Specifically, the firm released top-line data from a ...
Investors Dumping 4 Biotech Stocks - Idera Pharmaceuticals (IDRA ...  Wall Street Observer
WallStreet Morning Info: Idera Pharmaceuticals, Inc. (IDRA), ContraVir ...  WallStreet Scope
Idera Pharmaceuticals Provides Development Update on IMO-9200, an ...
CAMBRIDGE, Mass. and EXTON, Pa., May 18, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. IDRA, +2.96% a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases ...
Stock Update (NASDAQ:IDRA): Idera Pharmaceuticals Inc Provides ...  Smarter Analyst
Four Stocks going down: Idera Pharmaceuticals (NASDAQ:IDRA), Plains All ...
Idera Pharmaceuticals Inc (IDRA) declared the achievement of key development milestones for its product candidate IMO-9200, an antagonist of Toll-like receptors (TLRs) 7, 8 and 9. Specifically, the company recently stated top-line data from a Phase 1 ...
Biotech Stocks You Should Dump - Sequenom (SQNM), Idera Pharmaceuticals ...  Wall Street Observer
Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta ...
Over the last three trading sessions and over the past one month, Idera Pharmaceuticals Inc.'s shares have fallen by 1.78% and 5.41%, respectively.